SUPERNUS PHARMACEUTICALS, INC. Proceeds from Sale of Intangible Assets
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Proceeds from Sale of Intangible Assets of $1.35 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2023-03-09
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale of intangible assets for the quarter ending 2014-09-30 was $30.00M.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from sale of intangible assets for fiscal 2019 was $1.35M.
| Period end | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|
| 2019-12-31 | $1.35M 10-K · filed 2020-02-28 | |
| 2014-09-30 | $30.00M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |